Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Floorless Preferred Stock/Debenture -- Ignore unavailable to you. Want to Upgrade?

To: jjs_ynot who wrote (1315)	7/8/2001 2:31:27 AM
From: BDR	Respond to of 1438

Unless there has been another amendment it looks like TMGU will lose its license for its only product, Remune, by August, 2001. Remune is still in trials and I don't see that they have marketing approval from Thailand. I may be missing something but this company looks like it's on the critical list. Trinity Medical Group USA, Inc. Announces Amendment of License Agreement With The Immune Response Corporation. Issue: Oct 9, 2000 SAN RAFAEL, Calif., Oct. 9 /PRNewswire/ -- Trinity Medical Group USA, Inc. (OTC: TMGU) announces the amendment of its license agreement for REMUNE(TM) with The Immune Response Corporation that extends the time requirement for marketing approval of REMUNE by Thailand Authorities. The License and Collaboration Agreement between the Company and The Immune Response Corporation had previously set Dec. 31, 2000 as a possible termination date of the agreement if Thailand governing health authorities had not granted the required marketing approval of REMUNE by then. The amendment removes that time requirement and the earliest possible termination date is now August 2001.

To: jjs_ynot who wrote (1315)	7/8/2001 10:45:47 AM
From: xcr600	Respond to of 1438

This mess looks like it might be floorless as well but I'm getting lost in the "wordiness" of it all. Anyone else care to take a crack at it?-- 10kwizard.com On June 29, 2001, ViroLogic, Inc. (“ViroLogic”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with several large investors (collectively, the “Purchasers”), pursuant to which ViroLogic agreed to issue and sell to the Purchasers, and the Purchasers agreed to purchase from ViroLogic, an aggregate of 1,625 shares (the “Shares”) of ViroLogic’s Series A Convertible Preferred Stock, and warrants to purchase an aggregate of 3.19 million shares of ViroLogic’s common stock (the “Warrants”), for an aggregate purchase price of $16.25 million in a private placement (the “Financing”). The Purchase Agreement contemplates two closings, each for a portion of the Shares and the Warrants. The first closing (the “First Closing”) occurred on July 2, 2001 and Virologic received gross proceeds of $6.65 million. The second closing (the “Second Closing”) is subject to approval by ViroLogic’s stockholders and other terms and conditions specified in the Purchase Agreement. The rights, preferences and privileges of the Series A Convertible Preferred Stock are set forth in the Certificate of Designations, Preferences and Rights filed with the Delaware Secretary of State. The Warrants are subject to the terms and conditions of the Stock Purchase Warrant issued by ViroLogic and evidencing the Warrants. Pursuant to two Registration Rights Agreements, ViroLogic has agreed to prepare and file with the Securities and Exchange Commission registration statements, following the First Closing and Second Closing, respectively, covering the resale of the shares of ViroLogic common stock issuable upon conversion of the Series A Convertible Preferred Stock and issuable upon exercise of the Warrants.